Unlock KRAS G12C for lung cancer treatment decisions

Webinar presenter, Anjen Chenn, MD, PhD, Medical Director, Center for Molecular Biology and Pathology, Discipline Director for Molecular Oncology, Labcorp, discusses the NCCN Guidelines® and the importance of KRAS G12C testing in NSCLC patients for a targeted therapy, KRAS G12C-a key emerging biomarker in non-small cell lung cancer (NSCLC), LUMAKRAS™-an approved treatment for NSCLC patients whose tumors harbor KRAS G12C mutations, and QIAGEN® therascreen® KRAS RGQ PCR Kit-an FDA-approved companion diagnostic to identify the KRAS G12C mutation. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast October 26, 2021.